Literature DB >> 20441242

Pharmacotherapy of bipolar disorder in children and adolescents: recent progress.

Jonathan C Pfeifer1, Robert A Kowatch, Melissa P DelBello.   

Abstract

Child and adolescent bipolar disorder (BPD) is a serious psychiatric disorder that often causes significant impairment in functioning. Pharmacological intervention is the cornerstone of treatment for bipolar youth, although psychotherapeutic interventions may be beneficial as adjunctive treatment. Medications used for the treatment of BPD in adults are still commonly used for bipolar children and adolescents. With the recent US FDA indication of risperidone, aripiprazole, quetiapine and olanzapine for the treatment of bipolar youth, the atypical antipsychotics are rapidly becoming a first-line treatment option. However, these agents are associated with adverse effects such as increased appetite, weight gain and type II diabetes mellitus. Although several evidence-based medications are now available for the treatment of BPD in younger populations, additional studies to evaluate the short- and long-term efficacy and potential for adverse events of these and other medications are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441242     DOI: 10.2165/11533110-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  106 in total

Review 1.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

2.  Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young.

Authors:  J Biederman; E Mick; T J Spencer; T E Wilens; S V Faraone
Journal:  J Child Adolesc Psychopharmacol       Date:  2000       Impact factor: 2.576

Review 3.  Pharmacological treatment of pathologic aggression in children.

Authors:  Drew H Barzman; Robert L Findling
Journal:  Int Rev Psychiatry       Date:  2008-04

4.  Medication use in children and adolescents treated in the community for bipolar disorder.

Authors:  Robinder K Bhangoo; Catherine H Lowe; Frances S Myers; Julia Treland; Justin Curran; Kenneth E Towbin; Ellen Leibenluft
Journal:  J Child Adolesc Psychopharmacol       Date:  2003       Impact factor: 2.576

Review 5.  The genetics of pediatric-onset bipolar disorder.

Authors:  Stephen V Faraone; Stephen J Glatt; Ming T Tsuang
Journal:  Biol Psychiatry       Date:  2003-06-01       Impact factor: 13.382

Review 6.  The use of atypical antipsychotics in pediatric bipolar disorder.

Authors:  Kiki D Chang
Journal:  J Clin Psychiatry       Date:  2008       Impact factor: 4.384

Review 7.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

Review 8.  One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review.

Authors:  Christoph U Correll; John M Kane
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-10       Impact factor: 2.576

Review 9.  Olanzapine for the treatment of bipolar disorder in children and adolescents.

Authors:  Jeffrey R Strawn; Melissa P Delbello
Journal:  Expert Opin Pharmacother       Date:  2008-02       Impact factor: 3.889

10.  Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics.

Authors:  Nick C Patel; Monica Hariparsad; Mary Matias-Akthar; Michael T Sorter; Drew H Barzman; John A Morrison; Kevin E Stanford; Stephen M Strakowski; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-06       Impact factor: 2.576

View more
  7 in total

Review 1.  Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 2.  The safety of olanzapine in young children: a systematic review and meta-analysis.

Authors:  Jacqueline Flank; Lillian Sung; Christopher C Dvorak; Wendy Spettigue; L Lee Dupuis
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

3.  Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities.

Authors:  Leslie Miller; Mark A Riddle; David Pruitt; Al Zachik; Susan dosReis
Journal:  J Behav Health Serv Res       Date:  2013-01       Impact factor: 1.505

4.  Pharmacotherapy and family-focused treatment for adolescents with bipolar I and II disorders: a 2-year randomized trial.

Authors:  David J Miklowitz; Christopher D Schneck; Elizabeth L George; Dawn O Taylor; Catherine A Sugar; Boris Birmaher; Robert A Kowatch; Melissa P DelBello; David A Axelson
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

5.  Diagnosing Alcohol and Cannabis Use Disorders in Adolescents with Bipolar Disorder: A Preliminary Investigation.

Authors:  Jessica J Black; Jaimee L Heffner; Robert M Anthenelli; Jennifer N Beavers; Allison Albertz; Thomas Blom; Caleb Adler; Melissa P Delbello
Journal:  J Dual Diagn       Date:  2012-02-13

Review 6.  Bipolar Spectrum Disorders in Male Youth: The Interplay between Symptom Severity, Inflammation, Steroid Secretion, and Body Composition.

Authors:  Andreas Walther; Marlene Penz; Daniela Ijacic; Timothy R Rice
Journal:  Front Psychiatry       Date:  2017-10-18       Impact factor: 4.157

7.  Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses.

Authors:  Caitlin S Yee; Emily R Hawken; Ross J Baldessarini; Gustavo H Vázquez
Journal:  Int J Neuropsychopharmacol       Date:  2019-08-01       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.